Drug-induced pulmonary disease

Area of Science:

• Pulmonology
• Pharmacology
• Internal Medicine

Background:

• Adverse drug reactions affecting the lungs are a significant cause of morbidity and mortality.
• Patients often lack awareness of potential side effects from both prescription and over-the-counter medications.
• Accurate drug history taking is essential for diagnosing unexplained medical conditions.

Purpose of the Study:

• To highlight the prevalence and types of drug-induced lung diseases.
• To emphasize the importance of physician vigilance in identifying medication-related pulmonary complications.
• To inform healthcare providers about specific drugs associated with adverse pulmonary effects.

Main Methods:

• Review of known medications causing pulmonary adverse effects.
• Identification of drug classes commonly associated with lung abnormalities.
• Analysis of reported pulmonary complications linked to specific drugs like amiodarone, ACE inhibitors, beta-blockers, aspirin, methotrexate, and chemotherapy agents.

Main Results:

• Over 100 medications can adversely affect the lungs, impacting airways, interstitium, and pleura.
• Cardiovascular drugs (amiodarone, ACE inhibitors, beta-blockers) and anti-inflammatory agents (aspirin, methotrexate) are frequent culprits.
• Chemotherapeutic agents can cause fatal lung disease, often mimicking infections in immunocompromised patients.

Conclusions:

• A thorough drug history is critical for diagnosing lung conditions potentially caused by medications.
• Increased physician and patient awareness of drug-induced lung disease is necessary.
• Early recognition and management of adverse drug reactions can improve patient outcomes and reduce healthcare costs.